✦ LIBER ✦

Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study

✍ Scribed by H. Schmidli; B. Peng; G-J. Riviere; R. Capdeville; M. Hensley; I. Gathmann; A. E. Bolton; A. Racine-Poon

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First line treatment of chronic phase ch

✍ Eskazan, Ahmet Emre; Ayer, Mesut; Kantarcioglu, Bulent; Arica, Deniz; Demirel, N 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

Prognostic factors for patients with chr

✍ Marin, D; Marktel, S; Bua, M; Szydlo, R M; Franceschino, A; Nathan, I; Foot, N; 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 123 KB

Imatinib mesylate versus allogeneic BMT

✍ Bittencourt, H; Funke, V; Fogliatto, L; Magalhães, S; Setubal, D; Paz, A; Macedo 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 165 KB

Efficacy and Safety of Imatinib Mesylate

✍ Yasuo Morishima; Michinori Ogura; Miki Nishimura; Fumiharu Yazaki; Masami Bessho 📂 Article 📅 2004 🏛 Carden Jennings Publishing 🌐 English ⚖ 93 KB

Sustained cytogenetic response after dis

✍ Waleed Ghanima; Johannes Kahrs; Tobias Gedde Dahl III; Geir E. Tjonnfjord 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

Survival of patients with chronic-phase

✍ David Marin; Sarah Marktel; Richard Szydlo; John P Klein; Marco Bua; Nicola Foot 📂 Article 📅 2003 🏛 The Lancet 🌐 English ⚖ 126 KB